A well-run medical spa produces 60 to 70 percent gross margin on neurotoxins and fillers after Allergan product cost, based on Spa Ledger client data across single-location practices.
Most QuickBooks files show 80 to 90 percent on the same treatments. Owners read the higher number, price off it, pay provider commissions against it, and wonder why the bank balance never matches the reported margin.
The mechanism is specific. Allergan sends PDF invoices to an email inbox.
Someone pays the card, the charge hits the bank feed, and a bookkeeper codes it to a generic "Supplies" expense or an uncategorized bucket. Treatment revenue flows in separately from Zenoti or AestheticsPro. The two sides of the transaction never meet on the P&L, so the financials read as if Botox costs the practice nothing to deliver.
Why the QuickBooks injectable margin is overstated
The default QuickBooks chart of accounts has no room for product-family COGS. When the books are set up without a CFO in the room, Allergan invoices land in one of three places: Supplies, Medical Supplies, or an uncategorized line the bookkeeper flags for review. None of these sit under Cost of Goods Sold, so the gross margin calculation skips vendor spend entirely.
The second failure mode is worse. Invoices never reach the books. The ops manager pays Allergan by credit card, the charge hits the bank feed, the bookkeeper codes it to Credit Card Charges and moves on. A $12,000 Botox order becomes noise. Nobody ever ties the charge back to the vial count it paid for.
| Line | QuickBooks default | Reconciled | What changed |
|---|---|---|---|
| Treatment revenue, 30 units | $390 | $390 | POS revenue is the same on both sides |
| Botox product COGS | $0 | $150 | Allergan invoice coded to COGS, not Supplies |
| Product gross profit | $390 | $240 | Real product profit before provider commission |
| Product gross margin | 100% | 62% | The 38-point gap is the Allergan invoice |
The six-step Allergan reconciliation
This is the process I run for every new Spa Ledger client in the first 30 days. It takes a few hours the first time and about 20 minutes a month after that. The output is a gross margin number the owner can actually price against.
-
1
Pull the last 90 days of Allergan invoices Open the email inbox that receives vendor invoices. Search "Allergan" and "invoice" across the last 90 days. Download every PDF into a single folder. Include Galderma, Merz, Evolus, and Revance in the same sweep if the practice uses them.
-
2
Extract vial count, product, and cost per vial For each invoice, record the product name (Botox, Juvéderm Ultra XC, Voluma, Dysport), vial or syringe count, and cost per unit or per syringe. A spreadsheet with columns for date, product, units, and cost is enough. Keep rebates and loyalty credits in a separate column.
-
3
Allocate units per treatment Use 20 to 50 units per Botox session depending on injection area. One syringe per filler treatment for Juvéderm and Volbella. Pull the actual unit count from the Zenoti or AestheticsPro treatment record. Generic assumptions understate waste and overstate margin.
-
4
Pull matching treatment revenue Export the treatment-level revenue report from Zenoti or AestheticsPro for the same 90-day window. Match the injectable product codes to the revenue codes. Every neurotoxin and filler unit sold should tie back to a vial and unit count from step 3.
-
5
Calculate actual COGS per treatment and gross margin Cost per unit times units delivered equals product cost per treatment. Treatment revenue minus product cost equals gross profit. Gross profit divided by revenue equals gross margin. A typical Botox treatment at $13 per unit retail and $5 per unit cost runs 62 percent product gross margin before provider commission.
-
6
Post to QuickBooks under product-family COGS accounts In QBO, code each Allergan invoice to "COGS, Neurotoxins" or "COGS, Fillers." Create these accounts under Cost of Goods Sold if they do not exist. Rerun the P&L by class. Service-line gross margin will be visible for the first time.
Worked example: one Botox treatment
The math is simple. What makes it useful is doing it against actual invoices instead of a vendor price sheet.
Multiply across treatment volume. A practice delivering 200 Botox treatments a month at this margin produces $48,000 in product gross profit. If the same owner reads 85 percent margin in QBO, they assume $66,300, price the service too low, and pay provider commissions calibrated to a number that does not exist. That $18,300 monthly gap is where cash disappears.
Coding Allergan invoices to a generic "Supplies" expense account below the gross profit line. The P&L still balances, but gross margin calculations skip vendor spend entirely. Supplies belongs under operating expenses for items like gloves and alcohol wipes. Neurotoxin and filler product cost belongs under Cost of Goods Sold, split by product family.
The invoice in your email is the real cost. Every point of margin above that is overhead you have not allocated yet.
Galderma, Merz, Evolus, and Revance
The same six-step process runs against every injectable vendor. Galderma invoices Dysport and Restylane. Merz invoices Xeomin, Radiesse, and Belotero.
Evolus invoices Jeuveau. Revance invoices Daxxify. Each one goes to a sub-account under COGS, Neurotoxins or COGS, Fillers, matched to the revenue code in the POS. Rebate programs (Allergan Partner Privileges, Galderma Aspire) apply as COGS credits in the period the rebate posts to the bank, not at invoice date.
Tracking vial waste and the gap it hides
A 100-unit Botox vial reconstituted with saline has a limited clinical window. Once opened, product left in the vial at end of day is either used the same day, stored with a waste log, or discarded. Most practices do not track the discard. The vial cost was paid, the units were not billed, and the gap disappears into the product-use variance every month.
A 5 percent waste rate on a practice running 100 vials per month is 500 units of unbilled product. At $5 per unit cost, that is $2,500 per month or $30,000 per year in product that left the practice as medical waste. The reconciliation in Step 5 above catches this gap because units delivered (from chart notes) will not match units purchased (from invoices). Investigate the delta before closing the month. Waste above 3 percent points to scheduling, dilution, or documentation issues that the clinical team can fix once the number is visible.
The practices that track vial waste as a line item on the weekly P&L see waste rates drop inside one quarter. The number itself drives the behavior. No waste report, no waste discipline.
Rebates, loyalty programs, and how they land on the books
Allergan Partner Privileges, Galderma Aspire, and Merz MyExperiences return rebate dollars or product credits based on volume tiers. The accounting question is not whether to track them. It is when and where to recognize them so the margin math stays honest month to month.
The cleanest treatment posts rebates as a credit to the matching COGS account in the period the rebate hits the bank or the credit memo applies. Rebate received against neurotoxin volume goes to COGS, Neurotoxins as a negative entry. Rebate received against filler volume goes to COGS, Fillers. Do not park rebate income in a generic "Other Income" line. That separates the rebate from the product it offsets and overstates the underlying COGS every month the rebate is expected but not yet posted.
Loyalty credits redeemed by patients at the front desk are a different problem. They reduce net revenue, not COGS. A $50 Alle credit applied to a $390 Botox treatment posts as $340 in treatment revenue. The reconciliation in Step 4 should pull net treatment revenue after loyalty redemptions, not gross menu price, or the margin math will come in 10 to 15 points too high on credit-heavy months.
Monthly cadence: what this looks like once it is running
The first reconciliation takes three to five hours because the 90-day vendor invoice pull and the 90-day POS export both need to be built from scratch. The invoices that were coded to Supplies across the last quarter need to be moved to COGS accounts. Rebate credits need to be identified and posted. This is a one-time catch-up.
After the first pass, the monthly cadence is 20 to 30 minutes. Download the month's Allergan, Galderma, Merz, Evolus, and Revance invoices. Post each to the correct COGS sub-account using the Products and Services items set up during the initial pass. Pull the treatment revenue export from Zenoti or AestheticsPro for the same month. Compare units purchased to units delivered. Flag any variance above 3 percent. Close the month. Repeat.
The weekly P&L that Spa Ledger clients receive on Mondays reflects this cadence. Injectable gross margin is a tracked line item, not a calculation the owner has to run in a spreadsheet. When margin slips from 62 percent to 57 percent in a week, the reconciliation data shows whether the cause was a large invoice landing, a vial waste spike, or a loyalty credit cluster. Each cause has a different operational fix.
What changes on the P&L
Once the reconciliation runs monthly, the P&L does three things it could not do before. Gross margin shows per service line, so the owner can see Botox margin separately from filler margin separately from laser margin.
Provider commissions can be calculated net of consumables, which is the only honest way to compensate an injector. And the injectable line on the P&L stops lying about how much of the revenue actually stays in the practice.
Your real injectable margin, reconciled every week.
Spa Ledger pulls Allergan, Galderma, Merz, Evolus, and Revance invoices every week and posts them to product-family COGS accounts in QuickBooks. You get weekly P&L by service line, gross margin per treatment, and provider commission math net of consumables. Your first month is free. No card required.
Reserve Your First Month